Comparison of the hypotensive effects of streptokinase-(human) plasmin activator complex and BRL 26921 (p-anisoylated streptokinase-plasminogen activator complex) in the dog after high dose, bolus administration.
In view of current interest in the possibility of rapid, high-dose administration of thrombolytic agents by the intravenous route in patients with coronary thrombosis (AMI), a study of this technique was carried out in the dog. Streptokinase-(human) plasmin activator complex (SK-Pm) and BRL 26921 (p-anisoylated streptokinase-(human) plasminogen activator complex) were each given at equivalent doses (28,500 IU/kg and 800 micrograms/kg respectively) to groups of beagle dogs by rapid injection over 10 sec and their effects on blood pressure, plasmin formation and kallikrein production were compared over the next 3h. SK-Pm produced, within 1-3 min, a pronounced hypotensive effect that was kinetically related to a rapid and steep rise in systemic plasmin and kallikrein concentrations. BRL 26921 had no hypotensive effect, the rise in plasmin production was slower and the rate and extent of kallikrein formation was significantly less than in the SK-Pm group.
D000818:Animals; D016255:Anistreplase; D004285:Dogs; D005260:Female; D006801:Humans; D007022:Hypotension / Q000139:chemically induced* / Q000201:enzymology / Q000503:physiopathology; D007275:Injections, Intravenous; D007700:Kinetics; D008297:Male; D010958:Plasminogen / Q000008:administration & dosage / Q000494:pharmacology*; D010960:Plasminogen Activators / Q000008:administration & dosage / Q000494:pharmacology*; D013300:Streptokinase / Q000008:administration & dosage / Q000494:pharmacology*
D016255:Anistreplase; D010958:Plasminogen; D013300:Streptokinase; D010960:Plasminogen Activators